> For the complete documentation index, see [llms.txt](https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/llms.txt). Markdown versions of documentation pages are available by appending `.md` to page URLs; this page is available as [Markdown](https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/natural-medicines/melatonin-in-oncology-study-notes/fibrotic-drivers-and-the-26-gene-signature.md). # Fibrotic Drivers and the 26-Gene Signature In oncology, fibrosis is not just scar tissue. It is part of the **desmoplastic survival program** around the tumour. That includes **ECM deposition**, collagen cross-linking, **CAF activation**, EMT pressure, tissue stiffening, and therapy resistance. ### Where fibrosis fits in the condensate model Fibrotic signalling sits mainly across two domains. * **Axis I:** nuclear condensates that switch fibrotic gene programs on * **Axis II:** state-transition condensates that drive EMT, invasion, and stromal adaptation That is why fibrosis, EMT, and phase separation overlap so strongly in this model. The main pathways in view are not obscure. They are the familiar pro-fibrotic cancer drivers: * **TGF-β or SMAD** * **YAP or TAZ** * **Wnt or β-catenin** * EMT transcription factors * epigenetic programs that lock these states in place ### Fibrosis-linked genes highlighted here #### SMAD3 SMAD3 is a core TGF-β effector. It drives collagen, fibronectin, and ECM-related transcription. It fits directly into **Axis I** nuclear condensate models. It helps run fibrotic transcription programs rather than just touching them indirectly. #### TWIST1 TWIST1 is a major EMT driver. It supports invasion, mesenchymal transition, and fibrotic remodelling. It also fits the enhancer-hub logic behind EMT and fibroblast-like transition states. #### VIM Vimentin marks and supports mesenchymal states. It links cell mechanics, invasion, and stromal-style behaviour. That matters in desmoplastic and metastatic niches where tumour cells take on more fibroblast-like features. #### YAP1 and WWTR1 (TAZ) These are central mechano-sensitive regulators. They connect tissue stiffness, fibroblast activation, EMT, and enhancer-level transcription. They are especially relevant where the matrix itself helps lock malignant behaviour in place. #### CTNNB1 (β-catenin) β-catenin helps maintain Wnt-driven transcription, EMT, and fibroblast activation. It also shows phase-separation relevance in nuclear signalling hubs. It cooperates with both **YAP or TAZ** and **TGF-β** in fibrotic remodelling. #### EZH2 and KDM1A (LSD1) These epigenetic enzymes help lock fibrotic and EMT programs in place. That makes them important to the idea of transcriptional memory inside condensate-like hubs. They are part of the reason these states can become durable rather than temporary. ### Why this matters for melatonin The melatonin literature already contains repeated **anti-fibrotic** and **anti-EMT** findings. These include effects on: * TGF-β or SMAD signalling * TWIST1 and vimentin expression * YAP or TAZ activity * oxidative and inflammatory drivers of fibroblast activation The 26-gene condensate signature gives those findings a more structural frame. It suggests melatonin may not just block single pathways. It may also make the **fibrotic transcription hubs themselves** less stable. ### Why these genes matter together These genes are not interesting only one by one. They help describe a tissue state. That state includes stromal activation, mechanical stiffening, EMT pressure, redox adaptation, and transcriptional persistence under stress. When those signals cluster together, the tumour gains a more durable survival niche. That is why a condensate-based view adds value here. It explains how many pro-fibrotic signals can reinforce each other physically, not just biochemically. ### How the anti-fibrotic literature lines up Across tumour and non-tumour fibrosis models, melatonin is repeatedly linked to: * lower **TGF-β or SMAD3** activity * lower **EMT pressure**, including **TWIST1** and **vimentin** patterns * lower **YAP or TAZ** signalling * lower oxidative and inflammatory activation of fibroblast-like states * lower activation pressure on CAF and myofibroblast behaviour That does not prove condensate disruption directly in patients. It does show that the anti-fibrotic literature and the condensate framework point in the same direction. ### Practical summary This is still a mechanistic model. It does, however, help connect several older observations into one picture: * melatonin reduces fibrotic signalling * melatonin reduces EMT pressure * melatonin changes redox and stress handling * those same processes help sustain oncogenic condensates ### Related pages * [Melatonin in Oncology - Study Notes](/myhealingcommunity-docs/natural-medicines/melatonin-in-oncology-study-notes.md) — the hub page that ties together the mitochondria, dosing, immune, phase-separation, and fibrosis sections * [Phase Separation in Oncology](/myhealingcommunity-docs/natural-medicines/melatonin-in-oncology-study-notes/phase-separation-in-oncology.md) — the oncogenic-condensate model, its three levers, and the chronotherapy angle * [Moderate-Dose Immune Effects and Timing](/myhealingcommunity-docs/natural-medicines/melatonin-in-oncology-study-notes/moderate-dose-immune-effects-and-timing.md) — the human oral adjunct literature, Th1 logic, and timing framework * [Dosing, Bioavailability, and Human Scaling](/myhealingcommunity-docs/natural-medicines/melatonin-in-oncology-study-notes/dosing-bioavailability-and-human-scaling.md) — how mouse and cell data translate into estimated human exposure, route limits, and bioavailability caveats * [High-Dose Mitochondria, RET, and ROS](/myhealingcommunity-docs/natural-medicines/melatonin-in-oncology-study-notes/high-dose-mitochondria-ret-and-ros.md) — the mechanistic RET, ROS, uncoupling, and apoptosis sequence behind the high-dose claim ### Key references * Phase separation and cancer review\ * Melatonin and cancer metabolism review\ * Additional condensate-linked cancer paper\ * Melatonin and Hippo-pathway cross-talk\ * Melatonin and cancer-treatment review with EMT context\ --- # Agent Instructions This documentation is published with GitBook. GitBook is the documentation platform designed so that both humans and AI agents can read, navigate, and reason over technical content effectively. Learn more at gitbook.com. ## Querying This Documentation If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question. Perform an HTTP GET request on the current page URL with the `ask` query parameter, and the optional `goal` query parameter: ``` GET https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/natural-medicines/melatonin-in-oncology-study-notes/fibrotic-drivers-and-the-26-gene-signature.md?ask=&goal= ``` `ask` is the immediate question: it should be specific, self-contained, and written in natural language. `goal` is optional and describes the broader end goal you are ultimately trying to accomplish on behalf of the user. GitBook uses it to tailor the answer towards what is most useful for that goal. The response will contain a direct answer to the question and relevant excerpts and sources from the documentation. Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.